Latest Compliance News

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

The Supreme Court of New South Wales has approved CoStar Group’s acquisition of Domain Holdings Australia, setting the stage for a significant ownership change and a special dividend payout to shareholders.

Tamawood Limited has posted an 18.5% increase in revenue for the year ended June 2025, alongside a modest rise in net profit, while maintaining a strong balance sheet and reinstating its dividend reinvestment plan.

Finexia Financial Group has ended talks on a major disposal deal and is managing loan defaults with fresh collateral, while expanding its childcare lending strategy.

FirstWave’s Q4 FY25 update reveals a slight revenue decline but highlights a strategic AWS partnership and new chairman appointment, signaling a pivotal growth phase.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

West African Resources Limited has unveiled an updated 10-year gold production plan, projecting a peak output of 569,000 ounces in 2029 supported by 12.2 million ounces in Mineral Resources and 6.5 million ounces in Ore Reserves.

Alkane Resources has completed its merger with Mandalay Resources, creating a dual-listed gold and antimony producer with a robust growth pipeline and a strong cash position.

News Corporation reported a robust fiscal 2025 with revenues climbing 2% to $8.45 billion and net income from continuing operations surging 71%. The company also announced a new $1 billion accelerated stock repurchase program, underscoring confidence in its financial strength.

Charter Hall Long WALE REIT reports a $118.3 million statutory profit for FY25, reversing last year's heavy loss, while maintaining stable distributions and actively managing debt facilities.

REA Group Ltd has reported robust FY25 results with a 15% increase in revenue and a 23% rise in core net profit, alongside a 31% lift in dividends. The company also announced the retirement of CEO Owen Wilson after a decade at the helm.

Mayne Pharma has firmly rejected a fresh termination notice from Cosette Pharmaceuticals alleging breaches related to FDA disclosure, escalating an ongoing contractual dispute with significant legal implications.